Estimating and interpreting the pharmacokinetic profiles of individual patients with hemophilia A or B using a population pharmacokinetic approach: communication from the SSC of the ISTH

Note: Funding Information: V. Blanchette has received honoraria for participating in educational events and advisory boards funded by Bayer, Biogen, Novartis, Novo Nordisk, Pfizer, and Shire. He is a member of Data Safety Monitoring Boards for Octa-pharma and Shire. He is Chair of the International Prophylaxis Study Group, a collaborative study group that receives funding support from Bayer, Biogen, CSL Behring, Novo Nordisk, Pfizer, and Shire. J. Blatny has received speaker’s fees from Bayer, Baxter, CSL Behring, Octa-pharma, Pfizer, and Novo Nordisk, and performed consultancy for Shire, Baxter, Novo Nordisk, and Pfizer. P. Collins has received research support from CSL Behring, consultancy fees from Novo Nordisk, Sobi, Shire, and CSL Behring, and sponsorship for meetings from Novo Nordisk, CSL Behring, and Shire. K. Fischer has received speaker’s fees from Bayer, Baxter, Biotest, CSL Behring, Biotest Octapharma, Pfizer, and Novo Nordisk, performed consultancy for Bayer, Baxter, Biogen, Freeline, Novo Nordisk, and Pfizer, and received research support from Bayer, Wyeth/Pfizer, Baxter, and Novo Nordisk. A. Iorio’s Institution has received project-based funding via research or service agreements with Bayer, Baxalta/Shire, Biogen Idec, Grifols, Novo Nordisk, Pfizer, and Octapharma. E. Neufeld has served as a consultant for Novo Nordisk, Genentech, Pfizer, CSL Behring, Kedrion, Genentech, and Octapharma. He is also a DSMB member for Bayer. His institution has received research funds from Octapharma. All authors are co-investigators in the Web Accessible Population Pharmacokinetic Service (WAPPS) research project.